You are here

  • Home
  • Archive
  • Volume 9, Issue Suppl 2
  • 435 Pegasus HNSCC, a platform study of SAR444245 (THOR-707, a pegylated recombinant non-alpha IL-2) with anti-cancer agents in patients with recurrent/metastatic head and neck squamous cell carcinoma

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
435 Pegasus HNSCC, a platform study of SAR444245 (THOR-707, a pegylated recombinant non-alpha IL-2) with anti-cancer agents in patients with recurrent/metastatic head and neck squamous cell carcinoma
Free

 

Online download statistics by month:

Online download statistics by month: November 2021 to November 2024

AbstractFullPdf
Nov 2021240018
Dec 20215609
Jan 202266025
Feb 202244014
Mar 2022186013
Apr 202270017
May 202252010
Jun 202250015
Jul 20221802
Aug 202256010
Sep 20223207
Oct 2022110016
Nov 20224005
Dec 20224606
Jan 20234204
Feb 20233206
Mar 20234803
Apr 202324010
May 2023402
Jun 20231405
Jul 2023809
Aug 20232407
Sep 20232802
Oct 20232805
Nov 20232804
Dec 20233806
Jan 20242405
Feb 20243003
Mar 20243207
Apr 20241403
May 20241603
Jun 20243207
Jul 2024805
Aug 20241808
Sep 20241605
Oct 20241406
Nov 2024809
Total15960291